352 related articles for article (PubMed ID: 36960185)
1. Prostate cancer bone metastases biology and clinical management (Review).
Archer Goode E; Wang N; Munkley J
Oncol Lett; 2023 Apr; 25(4):163. PubMed ID: 36960185
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Biology of Bone Metastases in Prostate Cancer.
Hensel J; Thalmann GN
Urology; 2016 Jun; 92():6-13. PubMed ID: 26768714
[TBL] [Abstract][Full Text] [Related]
4. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.
Gandaglia G; Karakiewicz PI; Briganti A; Passoni NM; Schiffmann J; Trudeau V; Graefen M; Montorsi F; Sun M
Eur Urol; 2015 Aug; 68(2):325-34. PubMed ID: 25108577
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer.
Labanca E; Yang J; Shepherd PDA; Wan X; Starbuck MW; Guerra LD; Anselmino N; Bizzotto JA; Dong J; Chinnaiyan AM; Ravoori MK; Kundra V; Broom BM; Corn PG; Troncoso P; Gueron G; Logothethis CJ; Navone NM
Eur Urol Oncol; 2022 Apr; 5(2):164-175. PubMed ID: 34774481
[TBL] [Abstract][Full Text] [Related]
6. The role of osteoclastic activity in prostate cancer skeletal metastases.
Keller ET
Drugs Today (Barc); 2002 Feb; 38(2):91-102. PubMed ID: 12532187
[TBL] [Abstract][Full Text] [Related]
7. The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases.
O'Hurley G; Prencipe M; Lundon D; O'Neill A; Boyce S; O'Grady A; Gallagher WM; Morrissey C; Kay EW; Watson RW
Prostate; 2014 Feb; 74(3):306-13. PubMed ID: 24249383
[TBL] [Abstract][Full Text] [Related]
8. Metastatic Prostate Cancer Cells Secrete Methylglyoxal-Derived MG-H1 to Reprogram Human Osteoblasts into a Dedifferentiated, Malignant-like Phenotype: A Possible Novel Player in Prostate Cancer Bone Metastases.
Antognelli C; Marinucci L; Frosini R; Macchioni L; Talesa VN
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638532
[TBL] [Abstract][Full Text] [Related]
9. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
10. Emerging Players in Prostate Cancer-Bone Niche Communication.
Furesi G; Rauner M; Hofbauer LC
Trends Cancer; 2021 Feb; 7(2):112-121. PubMed ID: 33274720
[TBL] [Abstract][Full Text] [Related]
11. Elevated Serum Sialic Acid Levels Predict Prostate Cancer As Well As Bone Metastases.
Zhang C; Yan L; Song H; Ma Z; Chen D; Yang F; Fang L; Li Z; Li K; Li D; Yu N; Liu H; Xu Z
J Cancer; 2019; 10(2):449-457. PubMed ID: 30719139
[No Abstract] [Full Text] [Related]
12. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol.
Thysell E; Surowiec I; Hörnberg E; Crnalic S; Widmark A; Johansson AI; Stattin P; Bergh A; Moritz T; Antti H; Wikström P
PLoS One; 2010 Dec; 5(12):e14175. PubMed ID: 21151972
[TBL] [Abstract][Full Text] [Related]
13. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
14. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.
Gandaglia G; Abdollah F; Schiffmann J; Trudeau V; Shariat SF; Kim SP; Perrotte P; Montorsi F; Briganti A; Trinh QD; Karakiewicz PI; Sun M
Prostate; 2014 Feb; 74(2):210-6. PubMed ID: 24132735
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
16. Bone metastases in prostate cancer: a targeted approach.
Storey JA; Torti FM
Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of developing visceral metastases at diagnosis in prostate cancer patients.
Xu N; Wu YP; Ke ZB; Liang YC; Tao X; Chen SH; Li XD; Cai H; Lin YZ; Lin TT; Xue XY
Transl Cancer Res; 2019 Jun; 8(3):928-938. PubMed ID: 35116832
[TBL] [Abstract][Full Text] [Related]
18. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
19. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
20. Procoxacin bidirectionally inhibits osteoblastic and osteoclastic activity in bone and suppresses bone metastasis of prostate cancer.
Kong D; Ye C; Zhang C; Sun X; Wang F; Chen R; Xiao G; He S; Xu J; Rao X; Ai J; Gao X; Li H; Su L
J Exp Clin Cancer Res; 2023 Feb; 42(1):45. PubMed ID: 36759880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
